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HumanT lymphocytes can be activated by interaction with different stimuli, in-
cluding antigens, mitogenic lectins, and antibodies directed to a number of well-
characterized cell surface membrane structures such as theCD3TCR complex, CD2
andCD28 (Tp44), and other less studied structures such as Tp45, Tp90, and Tp103
(CB.1) (1-7). Other activating agents such as the tumor promoter phorbol esters are
also able to trigger the proliferation of restingT cells, but they require the presence
of other comitogenic signals provided by Cat ' ionophores or antibodies specific for
CD3, CD2, or CD28 (8-12) .
During activation,T cells acquire a number of cell surface glycoproteins that are
expressedde novo after distinct kinetics of appearance . Some molecules such as IL-2,
transferrin andinsulin receptors, and 4F2 and EA-1 antigens appear early, even be-
fore DNA synthesis (13-18). Others such as HLA-DR, CB.1, Ta-1, TLiSAI, T10,
and VLA-1 appear later, on activated cells (13, 19-24) . In addition, new epitopes
have been detected after activation on humanCD2andmurine T200 molecules (3, 25) .
Antibodies specific for hormone or growth factor receptors have been shown to
mimic the functional effects of their ligands (26-28). Therefore, we have explored
the possibility that T cells might receive inductive proliferation signals by mAbs
directed to certain activation structures . This hasbeen analyzed by preparingmAbs
to activatedT lymphocytes and selecting for mAbs that both recognize activation
structures and induceT cell proliferation . In the course of these studies, five mAbs
have been isolated against activation molecules that are rapidlyexpressed on resting
lymphocytes upon treatment with different stimuli and that triggerT cell prolifera-
tion and IL-2 synthesis in the presence ofPMA. All mAbs are directed to an iden-
tical disulphide-linkedheterodimeric structure designated as activation inducermol-
ecule (AIM).' In this paper we characterize the structure and function of this
molecule .
This workwassupportedby grants fromINSALUD FISS (88/1739)andCAICYT (0456-84) .M. Cebrian
andM. Rinc6n were supported by fellowships from Ministerio de Educaci6nyCiencia . Address corre-
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Materials and Methods
Monoclonal Antibodies .
￿
The anti-CD3 mAb SPVT3b (29), and UCHT1 mAb (30) were
kindly provided byDr . De Vries (Unicet Laboratories, Dardilly, France) andDr. P C . Beverley
UCRF, London, UK), respectively . The anti-CD3 Leu-4was purchased from Becton Dick-
inson & Co . (Mountain View, CA). Two anti-IL-2-R (CD25) mAbs were used, the previ-
ously describedMAR 108 (31) and the TPl/6 mAb, which hasbeen generated in our labora-
tory. TheD3/9 mAbdirected to thehumanT200 (CD45) (32),TS2/18 anti-CD2 (33), B9.4.2
anti-CD8 (34), TSl/2 and TSl/16 anti-HLA-DR (33), FG1/8 anti-4F2 (35), HP2/1 antiVLA
mAb (36), and HP2/6 anit-CD4 (37) have been described previously . The anti-CD11b and
anti-CD20 mAbs were purchased from Coulter Immunology (Hialeah, FL) .
Cells.
￿
PBL were obtained from heparinized venous bloodof normal volunteers by Ficoll-
Hypaque (Pharmacia Fine Chemicals, Uppsala, Sweden) centrifugation .
T cells were purified from PBMC by removal of adherent cells on plastic petri dishes fol-
lowed by passage through a nylon wool column . CD4' and CD8' cell subsets were obtained
by treatment of purified T cells with complement and ascites fluids of anti-CD8 B9.4.2 or
anti-CD4 HP2/6, respectively, as described (37) . Phenotypic analysis of purifiedT cells by
flow cytometry showed that theT cell population contained >90% CD3' ; <1% CDllb' and
<1% CD20' cells . The CD8' subset showed a purity of>95% CD8' cells and <1% CD4'
cells . CD4' cells contained >94% CD4' cells and <2% CD8' cells .
Activation of PBL was carried out by culturing 10 6 cells/ml in the presence of PMA (2
ng/ml) and soluble anti-CD3 SPVT3b mAb (1 gl/ml) for 24 h, unless otherwise indicated .
Cells were cultured in RPMI medium (Flow Laboratories, Irvine, Scotland) supplemented
with 10% FCS, 2 HIM L-glutamine, and 50 pg/ml penicillin/streptomycin.
Hybridoma Production.
￿
BALB/c mice were injected intraperitoneally with 10' cells ofPBL
activated for 24h with PMA and anti-CD3 mAbon day -30 and intravenouslyon day -3 .
Spleen cells from two immunized mice were fused on day 0 with P3X63/Ag 8.653 mouse
myeloma cells at a ratio of 4:1 according to standard techniques (38) ; they were distributed
into 96-well plates (Costar, Cambridge, MA) and grown as described (39) . After 2 wk, hy-
bridoma culture supernatants were harvestedand screened by both induction ofTcell prolifer-
ation in the presence of PMA (2 ng/ml) and binding to activated but not to resting PBL .
Those hybridoma-secreting-positive antibodies were cloned twice in soft agar.
Ig subclasses of anti-AIM TP mAbs were determined by double immunodiffusion with
anti-mouse subclass-specific antibodies (Nordic Immunological Laboratories, Tilberg, The
Netherlands) .
Radiolabeling Immunoprecipitation, andElectrophoresis .
￿
Activated or resting PBL were radio-
iodinated with chloroglycoluril (Iodogen ; Pierce ChemicalsCo., Rockford, IL) (40) . The lysis
buffer was prepared in PBS ; pH 7.4, containing 1% Triton X-100, 1% hemoglobin, and 1
mM PMSF
For immunoprecipitation, equal amountsof input radioactivity of 125I-labeled cell lysates
were incubated with 100 pl ofmAbs containing culturesupernatant . To isolate immune com-
plexes, 100 pl of 187.1 anti-mouse x chainmAb followed by 30 t l ofproteinA from Staphylo-
coccus aureus coupled to Sepharose (Pharmacia Fine Chemicals) were added . Immunoprecipi-
tates were processed as previously described (41) and sampleswere subjected to SDS-PAGE
and autoradiography with enhancing screens .
FACSAnalysis.
￿
Flow cytometry analysis were performed on anEPICS-Ccytofluorometer
(Coulter Scientific, Harpeaden, United Kingdom) . Cells were incubated with mAb superna-
tants containing -100 pg/ml, followed by washing and labeling with FITC-labeled goat anti-
mouse Ig .
Proliferation Assays.
￿
PBL, in a number of 2 x 105 cells/well, were activated in triplicate
cultures with either (a)PMA (Sigma Chemical Co ., St . Louis, MO) at different concentra-
tions as indicated ; (b) soluble anti-CD3 mAb. Culture supernatant ofT3b was used at 1 pl/ml,
final dilution ; (c) anti-CD3 mAb (1 pl/ml) andPMA (2 ng/ml) ; (d) A23187 calcium iono-
phore 1 pM (Sigma Chemical Co.) . After 3 h of culture the cells were washed (three times)
by centrifugation for 3 min at 400g in complete RPMI and left in culture for another 69
h; or (e) 1% (vol/vol) final concentration of PHA (Difco Laboratories Inc., Detroit, MI) .
Proliferation assays were carried out in 96 U-bottomed microtiter plates in complete RPMI .CEBRIAN ET AL .
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The cultures were maintained in humidified atmosphere containing 5% C02 for 72 h . Cell
proliferation was estimated by [3H]TdR (1 gCi = 37 KBq; New England Nuclear, Boston,
MA) incorporation during the last 16 h of culture . Cells were harvested and the radioactivity
was measured in a liquid scintillation counter.
IL-2 Production Assay .
￿
PBL (2 x 10 5 cells/well) were cultured in 96-well microtiter plates .
The cells were activated with culture supernatants (50 ttl) from different mAbs or 1% PHA
in either the presence or absence of different concentrations of PMA . After 24 h, culture
supernatants were assayed for IL-2 activity as described (42) using the mouse T cell line
CTLL2 . The IL-2 concentration of each sample was referred to a standard preparation (Na-
tional Institutes of Health, Bethesda, MD) and expressed in units/milliter .
Analysis ofIL-2-R Expression .
￿
PBL were incubated in plastic plates (24 wells ; Costar, Cam-
bridge, MA) coated with purified anti-AIM TPI/8, anti-CD3 T3b, and antiVLA HP2/1
mAb in the presence and absence ofPMA . Culture plates were pretreated overnight with
the purified mAb diluted inPBS (20 Rg/ml, 250 pl/well) and throughly washed withmedium
before the addition of PBL (2 x 106 cells/ml) . Cultures were set up either in the absence
or presence ofPMA (2 ng/ml) . After 24 h, cell cultures were harvested and the expression
of IL-2-11 (CD25) was analyzed by immunofluorescence flow cytometry.
Results
Characterization ofAIM Antigens .
￿
mAbs were obtained against human PBL acti-
vated for 24 h with a comitogenic mixture ofPMA and anti-CD3 mAbs . Antibodies
were selected by their reactivity with activated PBL but not with resting cells, and
by their ability to induce cell proliferation in the presence ofPMA. Five different
cloned mAb-secretinghybridoma lines (TP) were obtained that fulfilled both selec-
tion criteria . As shown in Table I, the anti-AIM TPmAb triggered a high prolifera-
tive response ofPBL in the presence ofPMA, comparable in magnitude to that in-
duced by anti-CD3 mAb. However, the anti-AIM mAbs were not able to directly
activate PBL in the absence ofPMA as opposed to the anti-CD3 mAbs .
To characterize the target structures recognized by the anti-AIM mAb, immuno-
precipitation analyses were carried out from 1251-labeled cell lysates of either resting
or activated PBL (Fig . 1) . The five selectedTP mAbs precipitated an identical two-
TABLE I
Induction by anti-AIM mAb of the Proliferation of Human PBL
in the Presence ofPMA
PBL were cultured with different anti-AIM mAbs (50 ul culture supernatant/
well) either in the presence or in the absence ofPMA . Anti-CD45 and anti-CD3
mAbs were used as negative and positive controls, respectively . [3H]TdR in-
corporation was measured in triplicate on day 3 .
MAb Specificity Ig subclass
[ 3H]TdR incorporation
Without PMA PMA (2 ng/ml)
cpm x 10 -3
TPI/8 AIM IgG3 0 .5 47.2
TPI/22 AIM IgG3 0 .3 53.5
TPI/28 AIM IgG3 0.4 64.2
TPI/33 AIM IgGl 0.4 60 .1
TPI/55 AIM IgG2b 0.4 19 .1
133/9 CD45 IgGI 0.2 4.8
T3b CD3 IgG2a 20.7 52.0
Medium 0 .5 5.81624
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chain structure containing polypeptide subunits of 33 and 27 kD from activated
PBL (Fig . 1 A, lanes 8-12), but no material was precipitated from resting PBL (Fig .
1 B, lanes 8-12) . Similarly, the IL-2-R molecule was selectively precipitated from
activated PBL (Fig . 1,A and B, lane 2) . Conversely, the labeled CD3 polypeptides
were absent in precipitates with two different anti-CD3 mAbs from activated PBL
(Fig . 1 A, lanes 6 and 7) and were detected in the precipitates from resting PBL
(Fig . 1 B, lanes 6 and 7) . The CD3 antigen is modulated by this treatment and
disappeared from the cell surface membrane as described in previous reports (43,
44) . Other antigens such as CD2, CD8, and HLA-DR (Fig . 1 A and B, lanes 3-5,
respectively) were also included for comparison . TheAIM antigen complex appeared
to be a distinct molecular entity from the IL-2-R (CD25 antigen, 60 kD), the CD2
(50 kD), CD8(32 kD), or HLA-DR (34/29 kD) molecules (Fig . 1 A, lanes 2-5, respec-
tively) . TheAIMantigens displayed a molecularmass of 60 kDwhen analyzed under
nonreducing conditions that correspond to the sum of the molecular weights of the
two polypeptides resolved under reducing conditions (Fig . 2) .
FIGURE 1 . Immunoprecipita-
tion ofAIM antigens from ac-
tivatedand nonactivated PBL .
1251-labeled cell lysates from
PBL activated with PMA and
anti-CD3 mAb (A) or resting
PBL (B) were immunoprecipi-
tated with anti-AIM mAbs :
TPl/8, TPI/22, TPl/28, TPl/
33, TPl/55 (lanes 8-12, respec-
tively), P3X63mAb as negative
control (lane 1), anti-CD25
mAb (lane 2), anti-CD2 mAb
(lane 3), anti CD8 mAb (lane
4), anti-HLA-DR (TSl/2 or
TSI/16 ; lane 5, A or B, respec-
tively) and anti-CD3 mAb
(UCHTI and Leu-4, lanes 6-7,
respectively) . Reduced samples
were subjected to SDS-12%
PAGE and autoradiography.Studies of expression of AIM antigens on resting and activated PBL were also
performedby immunofluorescence flow cytometry. Resting PBL didnot express the
AIM antigens (Fig . 3 A), whereas the majority ofPBL activated for 24 h withPMA
andanti-CD3 mAbs were clearly stained by anti-AIM mAbs (Fig. 3 C) .Ahigh propor-
tion (86%) of the resulting activated cells were CD2+ T lymphocytes (data not
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FIGURE 2. Comparison of reduced and nonreduced proteins
precipitated by anti-AIM mAbs. 125I-labeled cell lysates fromPBL
activated with PMA and anti-CD3 mAbs were immunoprecipi-
tated with TP1/8 mAbs (lanes 1 and 3) or TPl/55 mAbs (lanes
2 and 4) as described . Samples were analyzed by SDS- 10% PAGE
in the presence (lanes 1-2) or absence (lanes 3-4) ofreducing agent .
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FIGURE 3 .
￿
Immunofluorescence flow cytometry analysis ofAIM expression on resting (A-B)
and activated PBL (C-D). Cells labeled with TPl/8 (dashed line) and TPl/55 (solid line) anti-AIM
mAbs (A and C), and antiTac, anti-CD3, and anti-CD45 mAbs (B and D) were analyzed on
a EPICS-C cytofluorometer (Coulter Electronics).
' AIM IL-2R
1
I :v
CD3 A CD45
/y I 'v 1 .
w.
AIM
i w
CDL"2R ^CD451626
￿
A HUMAN T CELL ACTIVATION INDUCER MOLECULE
shown) . The expression ofAIM under these activation conditions was higher than
that of other activation molecules such as the IL-2-R, both in terms of number of
positive cells and fluorescence intensity (Fig . 3 C-D) .
These results indicate thatAIMantigens are disulphide-linked heterodimeric struc-
tures selectively expressed on activated PBL and biochemically unrelated to other
activation antigens such as IL-2-R .
Induction ofAIMExpression.
￿
We analyzed the capacity ofdifferent inductive stimuli
or some mitogenic combinations to induceAIM expression . These comparative studies
indicated that phorbol ester (PMA) was the strongest inducer of AIM expression
even in the absence of other comitogenic signals (Fig. 4) . Stimuli such asPHA and
anti-CD3 mAbs were also able to trigger AIM expression . In contrast, the Cat +
ionophore A23187 failed to induce AIM antigens by itself. Interestingly, the AIM
expression observed on PBL activated for24 hwith differentmitogens was significantly
higher when compared with PBL activated for 3 d (Fig . 4) . Therefore, it was of in-
terest to explore the sequence of appearance of AIM on PBL treated with PMA
as compared with that of other early activation antigens . As observed in Fig. 5, 75%
ofPBL expressed AIM antigen after 3h oftreatment . The peak ofAIM expression
was reached at 24 h and then gradually decreased . The kinetics showed that AIM
expression considerably preceded that ofIL-2-R, and even that ofthe 4F2 molecule.
Nevertheless, AIM is an activation antigen that is de novo synthesized by PBL upon
addition ofthe activating agent since the induction of its expression on PBLbyPMA
was inhibited by pretreatment of cells with either inhibitors ofprotein orRNA syn-
thesis (data not shown) .
These results clearly showed that AIM is an activation antigen of lymphocytes
that canbe induced very rapidly by mitogenic stimuli such as phorbol esters, PHA,
and anti-CD3 mAbs .
Induction of Cell Proliferation by AntiAIM mAb.
￿
The comitogenic effect triggered
by anti-AIM mAb was analyzed in more detail by using different concentrations
of purified anti-AIM TPl/8 mAbs and PMA (Fig. 6) . The anti-AIM was able to
mediate its inductive effect on proliferation at 0.5 wg/ml and the effect was main-
tained within a wide range ofmAb concentrations (0.5-50 wg/ml) . The purified anti-
CD3mAb, included forcomparison, triggered proliferation at lowerconcentrations
than anti-AIM mAb (Fig. 6A) . The difference in the requirement ofanti-AIMmAb
doses compared with anti-CD3 could be attributed to the intrinsic characteristics
of theCD3TCR antigen complex through which cell proliferation can be triggered
without the requirement of any other comitogenic signal by using minor amounts
of antibody.
The functional effect on PBLproliferation mediated by anti-AIM mAb required
concentrations ofPMA equal or higher than 0.5 ng/ml (Fig . 6 B) . This submito-
genicconcentration ofPMA is enough to induce AIM expression (not shown) and,
subsequently, the bindingof anti-AIM mAb triggers the proliferativeresponse . Both
the expression of AIM and the proliferative response induced by PMA and anti-
AIMmAbwere observed on purifiedTlymphocytes (Table II, and data notshown) .
Moreover, the proliferative effects were also induced by anti-AIM mAb on purified
CD4T lymphocytes and, toalower extent, on purified CD8T cells (Table II) . Thus,
it appears that the effects of anti-AIM mAbs are not dependent on the presence of
accessory cells .CEBRIAN ET AL .
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FIGURE 5 .
￿
Kinetics of expression ofAIM and other activation antigens on PBL activated by
PMA. PBLwere activated with 20 ng/ml ofPMA. Expression of various antigens was studied
by immunofluorescence flow cytometry at different times . X63 was included as negative control
(dotted line) . Percentages of positive cells are indicated .
FIGURE 6 .
￿
(A)PBL proliferation by various concentrations of anti-AIM mAbs in the presence
ofPMA . PBL (2 x 105 cells/well) were cultured, in the presence of different concentrations of
purified TPl/8 mAbor anti-CD3 mAb and 2 ng/ml PMA, for3 d . [3H]TdR incorporation was
measured on day 3 . (B) Effect of various concentrations of PMA on the comitogenic activity
of anti-AIM mAbs . PBL were incubated with 10 Wg/ml ofTPl/8 in the presence of various con-
centrations of PMA. [3H]TdR uptake was measured after 3 d .Since
the expression ofAIM byPMA is a requirement for triggering of prolifera-
tion
by AIM antibodies, we further investigated the kinetics of the proliferative re-
sponse
induced through AIM, as compared with that of an antigen already expressed
by
resting T cells such as CD3 (Fig
.
7)
.
No significant differences were observed
in
time course of the proliferative responses induced by mAbs to AIM and to CD3
antigens
in the presence ofPMA
.
[3H]TdR incorporation peaks were observed at
day
3 and thereafter gradually decreased
.
These results indicate that once AIM is
expressed
after 3 h ofPMA treatment, the signal(s) provided by anti-AIM are trans-
duced
as rapidly as those triggered through molecules such as CD3, which are al-
ready
present on resting lymphocytes
.
As
shown above, other stimuli such as PHA or anti-CD3 were also able to induce
AIM
expression
.
Therefore, the comitogenic effect ofanti-AIM mAb with different
stimuli
was investigated (Table III)
.
The culture ofPBL with anti-AIM mAb in the
TABLE
II
Effect
of Anti-AIM mAb on the Proliferation of Purled T Lymphocytes
and
CD4 and CD8 T Cell Subsets
Different
purified peripheral blood T cell populations (2 x 105 cells/well) were cultured with
10
pg/ml of purified anti-AIM TP1/8 mAbs in either the presence or the absence ofPMA (2
ng/ml) .
[3H]TdR incorporation was measured in triplicate on day 3
.
The proliferative response
of
PBL treated with PMA either in the presence or absence of anti-AIM mAbs was 48,500
and
9,100 cpm, respectively
.
Time
(Days)
CEBRIAN
ET AL
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FIGURE
7
.
￿
Kinetics
ofproliferation ofhuman
PBL
in the presence ofPMA and anti-AIM
mAbs .
PBL were cultured with 1 gg/ml of
purified
TPl/8 anti-AIM mAb or anti-CD3
mAbs,
in either the presence or the absence
of
PMA (2 ng/ml)
.
[3H]TdR incorporation
was
measured in triplicate, at different days
.
Stimulus T
lymphocytes
[3H]TdR
incorporation
CD4'
lymphocytes
CD8'
lymphocytes
cpm
x 10-3
- 1 .7 0.4 1 .8
Anti-AIM 2 .4 2.3 3 .0
PMA 8 .2 8.4 3 .9
Anti-AIM
+ PMA
38 .9 39.2 12 .91630
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TABLE III
Comitogenic Effect of anti-AIM mAbs with Other Different Stimuli
PBL were stimulated with PMA (2 ng/ml), PHA (1 %), ionophore A23187 (1
pM), or plastic-coated anti-CD3 mAb (10 pg/ml) in the presence of different anti-
AIM, anti-CD3, or anti-CD45 mAb culture supernatants (250 pl/ml). [3H]TdR
incorporation was measured in triplicate after 3 d. 13H]TdR incorporation with
ionophore (1 pM) and PMA (2 ng/ml) was 55,808 cpm.
presence ofeither PHA oranti-CD3 resulted in an enhancement ofT cell prolifera-
tion as compared with the responses to PHA or anti-CD3 alone. As expected, no
proliferation was obtained with the combination of anti-AIM mAb and the Cat+
ionophoreA23187, an agent that, asshown above, does notinduce AIM expression.
All these results may indicate that anti-AIM mAb are providing the cells with
complementary signal(s) to protein kinase C activation. On the other hand, it ap-
pears thatbindingofanti-AIM mAbto itstarget structuresynergized withthe prolifer-
ative signals triggered by anti-CD3 or PHA.
TheEffect ofAntiAIMnzAbon CellProliferation IsExertedVia IL-2/IL-2-RPathway.
￿
The
effect ofdifferent anti-AIM mAbs on the IL-2 production by PBL in the presence
ofdifferentdoses ofPMA was examined (Table IV). An inductiveeffect on the IL-2
secretion byPBL wasobserved with threedifferent anti-AIM mAbs ina PMA dose-
dependent fashion, whereas no IL-2 synthesis was seen in the absenceofPMA. The
TABLE IV
Anti-AIM mAbs Induce IL-2 Production from PBL Cells
PBL were incubated with culture supernatants of different mAbs or 1 % PHA
either in the absence or in the presence ofdifferent concentrations ofPMA. IL-2
activity of culture supernatants harvested after 24 h was measured as described
in Materials and Methods.
Stimulus Specificity
IL-2
0
activity with added
2
PMA
10
(ng/ml):
20
U/ml
Medium - 0 0 2 2
PHA 17b - 4 21 29 41
T3b CD3 0 20 65 42
TP1/8 AIM 0 7 30 39
TPl/22 AIM 0 2 44 79
TPl/33 AIM 0 3 22 21
TP1/55 AIM 0 1 1 3
mAb Specificity
[3H]TdR
PMA
Incorporation with stimuli:
PHA Ionophore Anti-CD3
- 15 .6 60 2.9 67 .6
TP1/8 AIM 62.3 126.1 3.0 102 .4
TPl/22 AIM 56.3 119.6 3 .0 92 .0
TP1/28 AIM 115.6 128.2 4.1 114.3
TP1/33 AIM 83.5 109.6 4.7 122.6
TP1/55 AIM 37.7 113 3 .5 79.0
T3b CD3 128.4 84.8 - -
D3/9 CD45 17.4 71 - -CEBRIAN ET AL .
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magnitudeofthe IL-2 production caused by theanti-AIM mAbs at the highestPMA
concentration was comparable to that induced by either anti-CD3 mAb or PMA
under the same experimental conditions .
Interestingly, a fourth anti-AIM mAb (TPl/55) wasnot able to induce detectable
IL-2 secretion on PBL in spite of staining activated cells with the highest fluores-
cence intensity (Fig. 3) . This is in agreement with proliferation results shown above
where the anti-AIM TPl/55 mAb was the one displaying the lowest comitogenic
effect (Tables I and III) .
Next, it was of interest to study whether PBL activated through AIM were able
to express IL-2-R molecules . PBL activated withPMA in the presence of anti-AIM
expressed IL-2-R molecules similarly to cells activated with anti-CD3 (Fig. 8) . Con-
versely, PBLcultured with purified antiVLA control mAbs did not express detect-
able IL-2-R molecules .
Further evidence that the PBL proliferation triggered by anti-AIM mAbs was di-
rected via the IL2/IL-2-R pathway was obtained from inhibition experiments with
two different anti-IL-2-R mAbs. As shownin Table V, both anti-IL-2-receptor mAbs
were able to virtually abrogate the proliferation mediated by antiAIMmAbsandPMA.
Discussion
In thepresent study, the identification and initial biochemicaland functional char-
acterization of an AIM involved in the T cell activation mechanism is reported . A
functional approach wasundertaken in order to identify activation antigens through
whichTcells might receive mitogenic signals . Thus, the different mAbs that recog-
nize theAIM molecule were initially selectedby their ability to induce high prolifer-
ative responses in combination with phorbol esters .
The structure of theAIM molecule has been partially characterized . It is formed
by a disulphide-linked 60-kD heterodimeric complex with polypeptide subunits of
33 and 27 kD. Interestingly, the AIM molecules are activation antigens expressed
by activated T lymphocytes but absent on resting peripheral blood T cells. AIM
antigens are clearly distinct molecular entities from most well-characterized human
cell surface structures functionally involved in differentmolecular activation pathways .
FIGURE 8.
￿
Induction ofthe expression ofIL-
2-Rby anti-AIM mAbs . PBLwereincubated
into plates coated with purifiedanti-CD3, anti-
AIM, or antiVLAcontrol mAbs at 5 gg/well
in eitherthe absence or the presence ofPMA
(2 ng/ml). Cultures were harvested after 24
h. Cells were stained with either anti-CD25
or anti-CD45 mAbs and analyzed by flow
cytometry. X63 was used as a negative con-
trol (dotted lines) .1632
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TABLE V
Inhibitory Effect of Anti-IL-2-R mAbs on the Proliferation
Induced by anti-AIM rnAbs
PBL were activated withPMA (2 ng/ml) and two different concentrations ofTP1/8 anti-AIM
mAbs in the presence of culture supernatants of anti-IL2-R mAbs (250 ul/ml) or anti-CD45
mAbs (250 p1/ml) as a negative control . [ 3H)TdR incorporation was measured in triplicate
after 3 d .
Thus, on the basis of both cellular expression and molecular weight it is different
from CD3, CD2, and CD28 (1-4) and from the very recently described Tp45 and
Tp90 (5, 6) . Unlike these molecules, which are present on restingT cells, theAIM
molecule is an activation antigen selectively expressed by T lymphocytes activated
by different stimuli .
After activation with phorbol esters, theAIM appearance can be detected earlier
than other activation antigens such as IL-2-R and 4F2. In addition, AIM can also
be distinguished from early activation structures such as IL-2-R (14), transferrin
receptor (15), and 4F2 (17) by both molecular weight and function . It is also clearly
different from other intermediate and late activation antigens such as TLiSa 1 (22),
VLA-1 (24, 45), CB .1 (20), Tal (21), T305 (46), Tact (47), and LDAI (48) . AIM
and the recently described EA-1 (18) are similar in both molecular weight and ki-
netics of appearance . However, no functional role has been found for the EA-1 an-
tigen, whereas the functional relevance ofAIM molecules on the triggering ofT
cell activation and proliferation has been clearly demonstrated in this study. Fur-
thermore, additional differences in cell distribution can also be appreciated . Thus,
the EA-1 is expressed on the majority (60%) o£immature thymocytes (18), whereas
the AIM antigen is only detected in a small subset (8-10%) of medullary mature
thymocytes . (Cebrian, M., et al ., unpublished results) . Comparative cell distribu-
tion and biochemical studies will be required to ascertain whetherthe antigenic de-
terminants defined by the anti-EA-1 mAb and those defined by the anti-AIM are
located on identical or distinct molecular structures . We have also found that one
(TPl/55) outof the five anti-AIM TP mAbs presented in this studydisplayed different
functional and FAGS staining characteristics . Despite its higher reactivity with acti-
vatedT lymphocytes, the TPl/55 mAb has weak or no effect on the induction of
T cell proliferation and IL-2 production, respectively. Structure-function relation
studies are in progress to understand the distinct functional behavior of the AIM
mAbs . Recently, Cosulich et al . (49) have described anmAb directed to an activa-
tion antigen with molecular characteristics similar to AIM structures that inhibit
Stimulus Inhibitor (mAb) [ 3H]TdR incorporation
cpm x 10 -3
PMA - 10.8
PMA + anti-AIM (1 wg/ml) - 81 .1
Anti-CD45 (133/9) 82.4
Anti-IL-2-R (MAR 108) 37 .3
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different IL-1-dependent proliferative responses . In this sense, it will be also of in-
terest to search for other anti-AIM mAbs displaying inhibitory characteristics .
It is important to note that AIM molecules areT lymphocyte activation antigens
through which agonistic proliferative signals can be triggered by mAb binding as
opposed to othermAbs specific for molecules such as IL-2-R andtransferrin receptor
(14, 50-52), TLiSal (22), and LDAi (48) which have been reported to mediate in-
hibitory effects on T cell function . It is conceivable thatanti-AIM mAbs may mimic
the binding of a physiological ligand to its receptor and therefore trigger a similar
sequence of signals that include a strong induction oftheIL-2 synthesis/IL-2-R expres-
sion pathway . This is similar towhat has been described for phorbol esters and growth
factors in other cellular models (26-28) . Thus, in theinsulin system, insulin is needed
to act in concert with phorbol esters or permeable diacyglycerol for the induction
of cell proliferation and growth response of Swiss 3T3 cell line (27) . Similarly, the
activation and proliferation ofB lymphocytes triggered by mAbs directed to the B
cell activation markerCD23 in conjunction withPMA have also been reported (53),
and it is also remarkable thatasoluble proteolytic fragment ofCD23 may alsomimic
the effects of B cell growth factor (54) .
TheAIM molecules appear to play an important role for transducing signals that
are synergistic with those provided by phorbol esters, which are known to activate
protein kinase C. Theanti-AIMmAbs also enhancethe proliferative response mediated
by PHA or anti-CD3 mAb. The expression of AIM is induced by phorbol esters
alone, and is thus presumably dependent on protein kinase C activation . Studies
with inactive analogues ofPMA failed to induce AIM expression, whereas exoge-
nous phospholipaseC that directly generates diacylglycerol also triggered significant
AIM cellular expression (Cebrian,M ., et al ., manuscript in preparation) . It appears
clear in this system that phorbol esters are sufficient to induce AIM expression and,
ina second step, bindingof anti-AIM mAb allows thetriggering of the cell prolifera-
tive response . Whether the antibody alone is mitogenic or whether it requires the
persistent activation of protein kinase C will be a matter of further research. Alter-
natively, it is also possible to speculate whether AIM structures may represent ion
transporter molecules that canbe stabilized in an active conformation by mAbbinding,
providing a maintained signal complementary to that of protein kinase C activa-
tion . In this context, a Na+/Ca2' exchanger role has been assigned to the lympho-
cyte early activation antigen 4F2 since anti-4F2 mAb exerted inhibitory effects in
this cation exchanger activity (55) . The intracellular signals triggered by anti-AIM
mAbs still remainunknownand are currently under investigation . Experiments are
now in progress to determine wheter phosphoinositide turnover, Cat' fluxes, or in-
tracytoplasmic pH are affected by anti-AIM mAb binding .
Summary
In this report, we describe a novel activation antigen that appears very early after
Tcell activation and is absent in resting lymphocytes, through which agonistic prolifer-
ative signals can be triggered by mAb binding . It has been designated as activation
inducer molecule (AIM) and is a disulphide-linked heterodimeric structure con-
taining two polypeptide chains ofM, 33,000 and 27,000 . The expression ofAIM
can be induced by different activation stimuli such as PMA, PHA, or anti-CD3
mAb, but not by the Cat + ionophore A23187, and it precedes the expression of1634
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other activation molecules such as 4F2 or the IL-2-R . Once AIM antigens are ex-
pressed on lymphocytes after stimulation with submitogenic doses ofPMA, the binding
ofanti-AIM mAbs triggers a strong proliferative response . Furthermore, a comito-
genic effect ofthe anti-AIM mAbs is exerted in the presence of either PHA or anti-
CD3 mAb . The activation oflymphocytes throughAIM antigens induces both IL-2
and IL-2-R receptor synthesis and is inhibited by anti-IL-2-R mAbs .
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